 Welcome back everybody. I'm Peter Clausi the week before PDAC, but today we're not talking mining You're an investor until we're talking with ex-flight. Oh ex-flight. Oh trades is x ph y on the CSC And we have Hugh Rogers CEO with us. Hi Hugh. Hi Peter pleasure to be here. Thank you We last chatted about six months ago, and you gave us a roadmap to success We're here today to see how you're doing on that. I understand that you have some Certifications pending that's right. So our lead diagnostic product, which is a rapid point of care PCR test Is very close to commercialization. We have two milestones pending one is an ISO certification Which allows for distribution in Europe and the other is the CE mark Which is the formal commercial certification for sale sale ISO was big in the 1990s Everybody was getting ISO. Does it still really matter? It is you cannot be a distributor in Europe without ISO 13485 certification. So it is highly relevant It does matter then does good What's the difference between this test and other tests? So, you know, there's a few different types of tests out there There's PCR polymerase chain reaction, which is the gold standard for diagnostics. So this means a clinical Diagnosis of a COVID-19 infection. So there's PCR. That's the diagnostic And then there's other types of screening devices and these screening devices or tests would be let's say antigen or serology Antigen is looking for the viral protein serology is looking for antibodies within your blood So this is your immune reaction. So there's really a PCR antigen and then antibody tests and yours is is PCR so we're focused on In this particular product on let's say the gold standard so a diagnostic level Diagnostic level accuracy, but what we've Optimized is the speed and portability So what we're what we've designed is we believe to be the fastest and most portable PCR test available So we're targeting let's say pop-up labs satellite labs Minimal equipment use minimal training required. So is this up the nose in the mouth Or the other alternative they've been talking about in Japan No, so it's actually a versatile platform. So depending on the sample collection within the jurisdiction It can use either or so in Germany Right now it is nasal or oral We have not tried it with the other alternative It would probably work, but we're focused really on the oral the most convenient and least invasive You know you just said the other alternative, but Yeah, thank you Thanks, but you're the company is not a one-trick pony, you know to get a two dollar or three dollar share price You have to have more than one Skew for sale. I you also do cannabis based. You're looking at psychedelics. What else you doing? That's right. So I mean we're we're really trying to push the the boundaries of innovation when it comes to bio science We have even within our diagnostics portfolio a Pipeline of biosensor products and these are focused. We have h1n1 h5n1 We have a number of dental health applications It'll be coming to market this year right about the bird flu like there's wasn't it recently reported some bird flu somewhere in Asia Yeah, I mean bird flu pops up from time to time as well as swine flu Both of those are high risk pandemic threats. So we we're developing oral biosensors for those And that that's just our diagnostic portfolio. We have a drug development or drug formulation portfolio that includes a Rotigating Parkinson's patch We have a number of cannabinoid products oral dissolvable As well as we're now moving it to psychedelics and our psychedelic business is focused Three parts really the first is development of API So this is industrial scale production of pharmaceutical grade psychedelic compounds right now working on Biotechnology produced. So this is Genetically modified microorganisms producing psilocybin the second is the synthesis of pharmaceutical grade mescaline and Then we are reviewing other opportunities, but the second stage is drug delivery So we have a drug formulation business in Germany These are thin film both transdermal and sublingual or oral dissolvable those give your precise dose dosages, right? Exactly. So that's something that certainly holds back. I think the the psychedelic let's say world Our medicine generally is this sort of the idea and you look at something like I think well Mushrooms would be one imagine mushrooms and others peyote, which is mescaline but it's delivered currently through these basically pieces of cactus and There's really no way to standardize the amount of mescaline in there and there's a number of other compounds in both psilocybin and Let's say peyote that make you quite sick. So, you know often there's not a nausea or vomiting involved So what we're doing is developing standardized oral dissolvable delivery systems Precise dosing. It's repeatable. It's predictable. It's safer So we have the ISO coming up the other certification coming up. What else should we be looking forward to? Commercialization so I mean the big story right now is bringing a product to market It's a very attractive. We think it's a you know a new tool It's an optimization or an improvement on an existing product that can be Compatible or it is compatible with almost all currently used PCR equipment. Okay, good We will check in again then just as we did this time X phytotherapeutics corp is the full name of the company XPHY on the Canadian Securities Exchange Hugh Rogers the CEO and formative as ever Thanks so much Peter signing off from investor Intel. I'm Peter Closie. Have a safe day